Eli Lilly to market Taisho’s diabetes drug
The company has secured the rights to develop and market the oral DPP-IV inhibitor, known as TS-021, which is currently in phase I clinical development for the treatment
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.